of the US population has NAFLD
of the US population with NAFLD have NASH
Rimidi’s Approach to Fatty Liver Disease
The prevalence of obesity coupled with an aging population is making NAFLD and NASH the next silent epidemic in healthcare. Rimidi provides a comprehensive, progressive model of care that supports providers--from screening at-risk populations to risk stratification to get each patient to the appropriate level of care.
Identify At-Risk Patients
Whether a patient engages the health system through primary care, bariatrics, endocrinology or hepatology, Rimidi’s platform helps aggregate patient data directly through the EHR and identify the population at risk of NAFLD and NASH.
Once a patient is identified as at-risk, Rimidi provides a progressive care model, guiding physicians to the right level of intervention— whether that’s a specialist referral, bloodwork, or imaging.